NCT07449754 2026-03-04
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Hanmi Pharmaceutical Company Limited
Phase 2 Recruiting
Clinical Trials
31 trialsNCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04835805 2026-02-03
A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.
Genentech, Inc.
Phase 1 Active not recruiting
NCT04109456 2026-01-15
IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma
InxMed (Shanghai) Co., Ltd.
Phase 1 Completed
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT03175432 2025-11-03
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT02902029 2025-04-09
ImmunoCobiVem
University Hospital, Essen
Phase 2 Completed
NCT04722575 2025-03-13
NEO-TIM
Fondazione Melanoma Onlus
Phase 2 Active not recruiting
NCT03101254 2024-07-17
LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT03625141 2024-04-11
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT05756556 2024-02-01
T3011 in Combination With Cobimetinib in Patients With Advanced Melanoma
ImmVira Pharma Co. Ltd
Phase 2 Suspended
NCT03430947 2023-09-14
RadioCoBRIM
Technische Universität Dresden
Phase 2 Terminated
NCT02414750 2022-11-30
REPOSIT
Netherlands Working Group on Immunotherapy of Oncology
Phase 2 Terminated
NCT02036086 2022-10-27
Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases
Sunnybrook Health Sciences Centre
Phase 2 Unknown
NCT01689519 2022-05-02
coBRIM
Hoffmann-La Roche
Phase 3 Completed
NCT01959633 2022-02-24
VEMUPLINT
Fondazione Melanoma Onlus
Phase 1/2 Completed
NCT02818023 2022-01-03
Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma
University of Pittsburgh
Phase 1 Terminated
NCT03178851 2021-11-19
Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT03224208 2021-04-26
VECODUE
Fondazione Melanoma Onlus
Phase 2 Terminated
NCT02303951 2021-02-03
NEO-VC
University Hospital Tuebingen
Phase 2 Terminated
NCT01656642 2020-07-21
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Genentech, Inc.
Phase 1 Completed
NCT02537600 2020-01-27
CONVERCE
Center Eugene Marquis
Phase 2 Completed
NCT02768207 2019-08-28
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01271803 2019-07-29
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01813214 2019-02-26
The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma
Georgetown University
Phase 2 Terminated
NCT03139513 2019-01-22
MELANIS
Hoffmann-La Roche
Completed
NCT02457793 2018-11-20
A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Completed
NCT01495988 2017-10-24
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Melanoma Research Foundation Breakthrough Consortium
Phase 2 Terminated
NCT02427893 2016-11-15
Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 3 Withdrawn